AxoGen (NASDAQ:AXGN) Announces Earnings Results

AxoGen (NASDAQ:AXGN) announced its quarterly earnings data on Wednesday. The medical equipment provider reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.08, FiscalAI reports. The business had revenue of $75.83 million during the quarter, compared to the consensus estimate of $73.18 million.

Here are the key takeaways from AxoGen’s conference call:

• Positive Sentiment: AxoGen reported third-quarter revenue of $75.8 million, up 26.2% year over year, with breast revenue increasing more than 60% and adjusted EBITDA rising 46% to $13.4 million. Management raised 2026 guidance to at least $290 million in revenue, including $7 million from BioCircuit, while maintaining expectations for at least 73% gross margin and positive free cash flow.
• Positive Sentiment: Commercial payer coverage for Avance reached approximately 96% of U.S. covered lives after Elevance removed its nerve-gap restriction and Aetna added coverage for certain upper-extremity repairs. The company said breast growth is supported by expanding account adoption, with roughly 485 active breast accounts and 590 active surgeons.
• Positive Sentiment: AxoGen completed its $200 million BioCircuit acquisition, adding NerveTape and access to direct nerve-repair procedures representing an estimated 40%–50% of transected nerve cases. Management expects the product to contribute to revenue growth and adjusted EBITDA margin in its first year, although integration and potential cannibalization risks remain.
• Negative Sentiment: Gross margin declined to 74.8% from 76.6% a year earlier and is expected to decrease sequentially in the fourth quarter as production shifts toward longer Avance grafts for breast procedures. The company also warned that BioCircuit purchase-accounting inventory adjustments could further pressure fourth-quarter and full-year gross margin, while higher amortization and administrative expenses are expected going forward.
• Positive Sentiment: AxoGen plans to begin prostate nerve-reconstruction market development in 2027 after treating more than 220 patients across 15 sites; among patients with at least six months of follow-up, surgeons reported better-than-expected erectile-function recovery in approximately 80% and pad-free urinary continence above expected levels in more than 95%. Prostate is not included in current guidance, but management views it as a potentially meaningful long-term growth driver.

AxoGen Trading Up 27.7%

AXGN stock traded up $10.38 during midday trading on Wednesday, reaching $47.84. 5,403,960 shares of the company traded hands, compared to its average volume of 1,176,874. AxoGen has a 52-week low of $18.46 and a 52-week high of $52.91. The business has a 50 day moving average of $42.80 and a 200-day moving average of $39.20.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Barclays cut their target price on shares of AxoGen from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, October 23rd. Bank of America initiated coverage on AxoGen in a report on Monday, October 12th. They issued a “buy” rating and a $52.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of AxoGen in a report on Wednesday, August 26th. HC Wainwright increased their price target on shares of AxoGen from $50.00 to $53.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Finally, Raymond James Financial upped their target price on shares of AxoGen from $48.00 to $53.00 and gave the stock an “outperform” rating in a research note on Friday, September 25th. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $51.27.

Insider Transactions at AxoGen

In other news, Director Amy Wendell sold 13,353 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $48.42, for a total transaction of $646,552.26. Following the transaction, the director directly owned 107,976 shares in the company, valued at approximately $5,228,197.92. This trade represents a 11.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathy Weiler sold 14,150 shares of AxoGen stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $45.30, for a total transaction of $640,995.00. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 98,503 shares of company stock worth $4,656,947 over the last three months. Company insiders own 2.44% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.